SUMMARY
This case provides the first in vivo evidence suggesting a possible synergistic effect between venetoclax and ICIs, potentially triggering haemophagocytic lymphohistiocytosis (HLH). This underscores the importance of vigilance and tailored management in the era of evolving cancer therapies to mitigate potentially life-threatening complications. HLH management often relies on expert opinion and limited case reports. This case contributes valuable clinical insights that may inform future treatment approaches.
(BELG J HEMATOL 2025;16(3):125–9)
